You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIdarubicin
Accession NumberDB01177  (APRD00126)
TypeSmall Molecule
GroupsApproved
DescriptionAn orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem]
Structure
Thumb
Synonyms
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-
Idarubicina
Idarubicine
Idarubicinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aj-idarubicinsolution1 mgintravenousAgila Jamp Canada IncNot applicableNot applicableCanada
Idamycin - Cap 10mgcapsule10 mgoralPfizer Canada Inc1996-12-312006-08-02Canada
Idamycin - Cap 25mgcapsule25 mgoralPfizer Canada Inc1996-12-302006-08-02Canada
Idamycin - Cap 5mgcapsule5 mgoralPfizer Canada Inc1996-12-312006-08-02Canada
Idamycin PFSsolution1 mg/mLintravenousPharmacia and Upjohn Company1997-02-17Not applicableUs
Idamycin PFSsolution1 mg/mLintravenousPharmacia and Upjohn Company1997-02-17Not applicableUs
Idamycin PFSsolution1 mg/mLintravenousPharmacia and Upjohn Company1997-02-17Not applicableUs
Idamycin PFSsolution1 mgintravenousPfizer Canada Inc2006-11-25Not applicableCanada
Idamycin Powder -5mg/vialpowder for solution5 mgintravenousPfizer Canada Inc1995-12-312014-03-21Canada
Idamycin Powder -10mg/vialpowder for solution10 mgintravenousPfizer Canada Inc1995-12-312014-03-21Canada
Idamycin Pws 10mg/vialpowder for solution10 mgintravenousAdria Laboratories Of Canada Ltd.1991-12-311996-09-10Canada
Idamycin Pws 5mg/vialpowder for solution5 mgintravenousAdria Laboratories Of Canada Ltd.1991-12-311996-09-10Canada
Idarubicinsolution1 mgintravenousPfizer Canada Inc2014-11-04Not applicableCanada
Idarubicin Hydrochloride Injectionsolution1 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Idarubicin Hydrochloride Injectionsolution1 mgintravenousFresenius Kabi Canada Ltd2010-04-13Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Idarubicin Hydrochlorideinjection1 mg/mLintravenousSandoz Inc2011-03-29Not applicableUs
Idarubicin Hydrochlorideinjection, solution1 mg/mLintravenousTeva Parenteral Medicines, Inc.2002-10-01Not applicableUs
Idarubicin Hydrochlorideinjection10 mg/10mLintravenousAmneal Agila, Llc2013-04-30Not applicableUs
Idarubicin Hydrochlorideinjection, solution1 mg/mLintravenousTeva Parenteral Medicines, Inc.2002-10-01Not applicableUs
Idarubicin Hydrochlorideinjection20 mg/20mLintravenousAmneal Agila, Llc2013-04-30Not applicableUs
Idarubicin Hydrochlorideinjection, solution1 mg/mLintravenousTeva Parenteral Medicines, Inc.2002-10-01Not applicableUs
Idarubicin Hydrochlorideinjection, solution1 mg/mLintravenousFresenius Kabi USA, LLC2009-08-11Not applicableUs
Idarubicin Hydrochlorideinjection5 mg/5mLintravenousAmneal Agila, Llc2013-04-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
IdamycinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Idarubicin Hydrochloride
Thumb
  • InChI Key: JVHPTYWUBOQMBP-RVFAQHLVSA-N
  • Monoisotopic Mass: 533.145259206
  • Average Mass: 533.955
DBSALT000341
Categories
UNIIZRP63D75JW
CAS number58957-92-9
WeightAverage: 497.4939
Monoisotopic: 497.168581467
Chemical FormulaC26H27NO9
InChI KeyInChIKey=XDXDZDZNSLXDNA-TZNDIEGXSA-N
InChI
InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
IUPAC Name
(7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
C[C@@H]1O[[email protected]](C[[email protected]](N)[C@@H]1O)O[[email protected]]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative Parents
Substituents
  • Anthracyclinone-skeleton
  • Anthracycline
  • Tetracenequinone
  • 1,4-anthraquinone
  • 9,10-anthraquinone
  • Anthracene
  • Amino sugar
  • Tetralin
  • Aryl ketone
  • Hydroquinone
  • Amino saccharide
  • Benzenoid
  • Oxane
  • Monosaccharide
  • Saccharide
  • Vinylogous acid
  • Tertiary alcohol
  • Alpha-hydroxy ketone
  • Secondary alcohol
  • Polyol
  • Ketone
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
PharmacodynamicsIdarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Mechanism of actionIdarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding97%
MetabolismNot Available
Route of eliminationThe drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.
Half life22 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
  • Bacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5153
Blood Brain Barrier-0.975
Caco-2 permeable-0.7492
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.7328
P-glycoprotein inhibitor IINon-inhibitor0.956
Renal organic cation transporterNon-inhibitor0.9214
CYP450 2C9 substrateNon-substrate0.8004
CYP450 2D6 substrateNon-substrate0.8937
CYP450 3A4 substrateSubstrate0.5419
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9439
CYP450 2D6 inhibitorNon-inhibitor0.9382
CYP450 2C19 inhibitorNon-inhibitor0.9316
CYP450 3A4 inhibitorNon-inhibitor0.9514
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9516
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9456
BiodegradationNot ready biodegradable0.9762
Rat acute toxicity4.3474 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9896
hERG inhibition (predictor II)Non-inhibitor0.882
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral25 mg
Capsuleoral5 mg
Solutionintravenous1 mg/mL
Solutionintravenous1 mg
Powder for solutionintravenous10 mg
Powder for solutionintravenous5 mg
Injectionintravenous1 mg/mL
Injectionintravenous10 mg/10mL
Injectionintravenous20 mg/20mL
Injectionintravenous5 mg/5mL
Injection, solutionintravenous1 mg/mL
Prices
Unit descriptionCostUnit
Idamycin pfs 1 mg/ml vial60.0USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.772 mg/mLALOGPS
logP1.69ALOGPS
logP1.9ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.55ChemAxon
pKa (Strongest Basic)8.95ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area176.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity126.43 m3·mol-1ChemAxon
Polarizability50.33 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Marco Villa, Roberto Arosio, Roberta Fretta, Nicola Diulgheroff, “Synthesis of idarubicin aglycone.” U.S. Patent US20060047108, issued March 02, 2006.

US20060047108
General ReferencesNot Available
External Links
ATC CodesL01DB06
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Idarubicin can be decreased when combined with Abiraterone.
AceclofenacAceclofenac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Idarubicin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Idarubicin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
AdapaleneAdapalene may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Alendronic acidIdarubicin may increase the hypocalcemic activities of Alendronic acid.
AmdinocillinThe serum concentration of Idarubicin can be decreased when it is combined with Amdinocillin.
AmiodaroneThe metabolism of Idarubicin can be decreased when combined with Amiodarone.
AmoxicillinThe serum concentration of Idarubicin can be decreased when it is combined with Amoxicillin.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Idarubicin.
AmpicillinThe serum concentration of Idarubicin can be decreased when it is combined with Ampicillin.
AntipyrineAntipyrine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ApremilastApremilast may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
AprepitantThe metabolism of Idarubicin can be increased when combined with Aprepitant.
ArtemetherThe metabolism of Idarubicin can be decreased when combined with Artemether.
AtomoxetineThe metabolism of Idarubicin can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
AzelastineAzelastine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
AzlocillinThe serum concentration of Idarubicin can be decreased when it is combined with Azlocillin.
BalsalazideBalsalazide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
BenoxaprofenBenoxaprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Benzathine benzylpenicillinThe serum concentration of Idarubicin can be decreased when it is combined with Benzathine benzylpenicillin.
BenzylpenicillinThe serum concentration of Idarubicin can be decreased when it is combined with Benzylpenicillin.
Benzylpenicillin PotassiumThe serum concentration of Idarubicin can be decreased when it is combined with Benzylpenicillin Potassium.
BetaxololThe metabolism of Idarubicin can be decreased when combined with Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Idarubicin.
Botulinum Toxin Type AIdarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.
Botulinum Toxin Type BIdarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
BromfenacBromfenac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Idarubicin.
BupropionThe metabolism of Idarubicin can be decreased when combined with Bupropion.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idarubicin.
CapecitabineThe metabolism of Idarubicin can be decreased when combined with Capecitabine.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Idarubicin.
CarbamazepineThe metabolism of Idarubicin can be increased when combined with Carbamazepine.
CarbenicillinThe serum concentration of Idarubicin can be decreased when it is combined with Carbenicillin.
CarboplatinIdarubicin may increase the ototoxic activities of Carboplatin.
CarprofenCarprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
CastanospermineCastanospermine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
CelecoxibCelecoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
CeritinibThe serum concentration of Idarubicin can be increased when it is combined with Ceritinib.
ChloroquineChloroquine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ChlorpromazineThe metabolism of Idarubicin can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Idarubicin can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Idarubicin can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Idarubicin can be decreased when combined with Cinacalcet.
CisplatinCisplatin may increase the nephrotoxic activities of Idarubicin.
CitalopramThe metabolism of Idarubicin can be decreased when combined with Citalopram.
ClemastineThe metabolism of Idarubicin can be decreased when combined with Clemastine.
ClobazamThe metabolism of Idarubicin can be decreased when combined with Clobazam.
ClodronateIdarubicin may increase the hypocalcemic activities of Clodronate.
ClomipramineThe metabolism of Idarubicin can be decreased when combined with Clomipramine.
ClonixinClonixin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ClotrimazoleThe metabolism of Idarubicin can be decreased when combined with Clotrimazole.
CloxacillinThe serum concentration of Idarubicin can be decreased when it is combined with Cloxacillin.
ClozapineThe risk or severity of adverse effects can be increased when Idarubicin is combined with Clozapine.
ClozapineThe metabolism of Idarubicin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Idarubicin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Idarubicin can be decreased when combined with Cocaine.
ColistimethateIdarubicin may increase the nephrotoxic activities of Colistimethate.
CyclacillinThe serum concentration of Idarubicin can be decreased when it is combined with Cyclacillin.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Idarubicin.
CyclosporineIdarubicin may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Idarubicin can be decreased when combined with Cyclosporine.
D-LimoneneD-Limonene may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
DabrafenibThe serum concentration of Idarubicin can be decreased when it is combined with Dabrafenib.
DarifenacinThe metabolism of Idarubicin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Idarubicin can be increased when it is combined with Darunavir.
DelavirdineThe metabolism of Idarubicin can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Idarubicin.
DesipramineThe metabolism of Idarubicin can be decreased when combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Idarubicin.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Idarubicin.
DiclofenacDiclofenac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
DicloxacillinThe serum concentration of Idarubicin can be decreased when it is combined with Dicloxacillin.
DiflunisalDiflunisal may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Idarubicin.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Idarubicin.
DigoxinDigoxin may decrease the cardiotoxic activities of Idarubicin.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Idarubicin.
DiphenhydramineThe metabolism of Idarubicin can be decreased when combined with Diphenhydramine.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Idarubicin.
DronedaroneThe metabolism of Idarubicin can be decreased when combined with Dronedarone.
DroxicamDroxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
DuloxetineThe metabolism of Idarubicin can be decreased when combined with Duloxetine.
EfavirenzThe metabolism of Idarubicin can be decreased when combined with Efavirenz.
EliglustatThe metabolism of Idarubicin can be decreased when combined with Eliglustat.
EpirizoleEpirizole may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Idarubicin.
EtanerceptEtanercept may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Etidronic acidIdarubicin may increase the hypocalcemic activities of Etidronic acid.
EtodolacEtodolac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
EtofenamateEtofenamate may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
EtoricoxibEtoricoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
EtravirineThe metabolism of Idarubicin can be decreased when combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
exisulindexisulind may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
FenbufenFenbufen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
FenoprofenFenoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idarubicin.
FingolimodIdarubicin may increase the immunosuppressive activities of Fingolimod.
FloctafenineFloctafenine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
FloxuridineThe metabolism of Idarubicin can be decreased when combined with Floxuridine.
FlucloxacillinThe serum concentration of Idarubicin can be decreased when it is combined with Flucloxacillin.
FluconazoleThe metabolism of Idarubicin can be decreased when combined with Fluconazole.
FlunixinFlunixin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
FluorouracilThe metabolism of Idarubicin can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Idarubicin can be decreased when combined with Fluoxetine.
FlurbiprofenFlurbiprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
FluvastatinThe metabolism of Idarubicin can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Idarubicin can be decreased when combined with Fluvoxamine.
FoscarnetFoscarnet may increase the nephrotoxic activities of Idarubicin.
FosphenytoinThe metabolism of Idarubicin can be increased when combined with Fosphenytoin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Idarubicin.
GemfibrozilThe metabolism of Idarubicin can be decreased when combined with Gemfibrozil.
HaloperidolThe metabolism of Idarubicin can be decreased when combined with Haloperidol.
HMPL-004HMPL-004 may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateIdarubicin may increase the hypocalcemic activities of Ibandronate.
IbuprofenIbuprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IbuproxamIbuproxam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IcatibantIcatibant may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ImipramineThe metabolism of Idarubicin can be decreased when combined with Imipramine.
IndinavirThe metabolism of Idarubicin can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IndoprofenIndoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IrbesartanThe metabolism of Idarubicin can be decreased when combined with Irbesartan.
IsoniazidThe metabolism of Idarubicin can be decreased when combined with Isoniazid.
IsoxicamIsoxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
KetoconazoleThe metabolism of Idarubicin can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacKetorolac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
LeflunomideThe risk or severity of adverse effects can be increased when Idarubicin is combined with Leflunomide.
LeflunomideLeflunomide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
LopinavirThe metabolism of Idarubicin can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Idarubicin can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
LosartanThe metabolism of Idarubicin can be decreased when combined with Losartan.
LovastatinThe metabolism of Idarubicin can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
LumacaftorThe serum concentration of Idarubicin can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Idarubicin can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
MannitolMannitol may increase the nephrotoxic activities of Idarubicin.
MasoprocolMasoprocol may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
MecamylamineIdarubicin may increase the neuromuscular blocking activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Mefenamic acidMefenamic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
MeloxicamMeloxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
MesalazineMesalazine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Idarubicin.
MethadoneThe metabolism of Idarubicin can be decreased when combined with Methadone.
MethotrimeprazineThe metabolism of Idarubicin can be decreased when combined with Methotrimeprazine.
MeticillinThe serum concentration of Idarubicin can be decreased when it is combined with Meticillin.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Idarubicin.
MetoprololThe metabolism of Idarubicin can be decreased when combined with Metoprolol.
MezlocillinThe serum concentration of Idarubicin can be decreased when it is combined with Mezlocillin.
MifepristoneThe serum concentration of Idarubicin can be increased when it is combined with Mifepristone.
MirabegronThe metabolism of Idarubicin can be decreased when combined with Mirabegron.
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NabumetoneNabumetone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NafcillinThe serum concentration of Idarubicin can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NaproxenNaproxen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NatalizumabThe risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.
NCX 4016NCX 4016 may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NevirapineThe metabolism of Idarubicin can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Idarubicin can be decreased when combined with Nicardipine.
Niflumic AcidNiflumic Acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
NilotinibThe metabolism of Idarubicin can be decreased when combined with Nilotinib.
NimesulideNimesulide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
OlopatadineOlopatadine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
OlsalazineOlsalazine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
OmeprazoleThe metabolism of Idarubicin can be decreased when combined with Omeprazole.
OrgoteinOrgotein may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
OuabainOuabain may decrease the cardiotoxic activities of Idarubicin.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Idarubicin.
OxacillinThe serum concentration of Idarubicin can be decreased when it is combined with Oxacillin.
OxaprozinOxaprozin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin.
PamidronateIdarubicin may increase the hypocalcemic activities of Pamidronate.
PanobinostatThe metabolism of Idarubicin can be decreased when combined with Panobinostat.
ParecoxibParecoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe metabolism of Idarubicin can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Idarubicin can be decreased when it is combined with Peginterferon alfa-2b.
PhenobarbitalThe metabolism of Idarubicin can be increased when combined with Phenobarbital.
PhenoxymethylpenicillinThe serum concentration of Idarubicin can be decreased when it is combined with Phenoxymethylpenicillin.
PhenylbutazonePhenylbutazone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
PhenytoinThe metabolism of Idarubicin can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Idarubicin.
PiperacillinThe serum concentration of Idarubicin can be decreased when it is combined with Piperacillin.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Idarubicin.
PirfenidonePirfenidone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
PiroxicamPiroxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
PivampicillinThe serum concentration of Idarubicin can be decreased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Idarubicin can be decreased when it is combined with Pivmecillinam.
PrimidoneThe metabolism of Idarubicin can be increased when combined with Primidone.
Procaine benzylpenicillinThe serum concentration of Idarubicin can be decreased when it is combined with Procaine benzylpenicillin.
PromazineThe metabolism of Idarubicin can be decreased when combined with Promazine.
PropacetamolPropacetamol may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
PTC299PTC299 may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Idarubicin can be decreased when combined with Pyrimethamine.
QuinidineThe metabolism of Idarubicin can be decreased when combined with Quinidine.
QuinineThe metabolism of Idarubicin can be decreased when combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Idarubicin is combined with Rabies vaccine.
RanolazineThe metabolism of Idarubicin can be decreased when combined with Ranolazine.
ResveratrolResveratrol may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Idarubicin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Idarubicin can be increased when combined with Rifapentine.
RisedronateIdarubicin may increase the hypocalcemic activities of Risedronate.
RitonavirThe metabolism of Idarubicin can be decreased when combined with Ritonavir.
RofecoxibRofecoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
RoflumilastRoflumilast may increase the immunosuppressive activities of Idarubicin.
RolapitantThe metabolism of Idarubicin can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Idarubicin can be decreased when combined with Ropinirole.
SalicylamideSalicylamide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Salicylic acidSalicylic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
SalsalateSalsalate may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
SecobarbitalThe metabolism of Idarubicin can be increased when combined with Secobarbital.
SeratrodastSeratrodast may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
SertralineThe metabolism of Idarubicin can be decreased when combined with Sertraline.
SildenafilThe metabolism of Idarubicin can be decreased when combined with Sildenafil.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idarubicin.
SorafenibThe metabolism of Idarubicin can be decreased when combined with Sorafenib.
SRT501SRT501 may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
StiripentolThe metabolism of Idarubicin can be decreased when combined with Stiripentol.
SulbactamThe serum concentration of Idarubicin can be decreased when it is combined with Sulbactam.
SulfadiazineThe metabolism of Idarubicin can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Idarubicin can be decreased when combined with Sulfamethoxazole.
SulfasalazineSulfasalazine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
SulfisoxazoleThe metabolism of Idarubicin can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
SuprofenSuprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Idarubicin.
Technetium Tc-99m MedronateIdarubicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.
TenofovirThe serum concentration of Idarubicin can be increased when it is combined with Tenofovir.
TenoxicamTenoxicam may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TepoxalinTepoxalin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TerbinafineThe metabolism of Idarubicin can be decreased when combined with Terbinafine.
TeriflunomideTeriflunomide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Idarubicin.
ThioridazineThe metabolism of Idarubicin can be decreased when combined with Thioridazine.
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TicagrelorThe metabolism of Idarubicin can be decreased when combined with Ticagrelor.
TicarcillinThe serum concentration of Idarubicin can be decreased when it is combined with Ticarcillin.
TiclopidineThe metabolism of Idarubicin can be decreased when combined with Ticlopidine.
TiludronateIdarubicin may increase the hypocalcemic activities of Tiludronate.
TipranavirThe metabolism of Idarubicin can be decreased when combined with Tipranavir.
TofacitinibIdarubicin may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Idarubicin can be decreased when combined with Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TolmetinTolmetin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Idarubicin.
TranilastTranilast may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
TranylcypromineThe metabolism of Idarubicin can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Idarubicin.
TrimethoprimThe metabolism of Idarubicin can be decreased when combined with Trimethoprim.
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ValdecoxibValdecoxib may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Valproic AcidThe metabolism of Idarubicin can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Idarubicin can be decreased when combined with Valsartan.
VancomycinVancomycin may increase the nephrotoxic activities of Idarubicin.
VenlafaxineThe metabolism of Idarubicin can be decreased when combined with Venlafaxine.
VoriconazoleThe metabolism of Idarubicin can be decreased when combined with Voriconazole.
ZafirlukastThe metabolism of Idarubicin can be decreased when combined with Zafirlukast.
ZaltoprofenZaltoprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ZileutonZileuton may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
ZiprasidoneThe metabolism of Idarubicin can be decreased when combined with Ziprasidone.
Zoledronic acidIdarubicin may increase the hypocalcemic activities of Zoledronic acid.
ZomepiracZomepirac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Zahraei Z, Rabbani-Chadegani A: A comparison of the effect of anticancer drugs, idarubicin and adriamycin, on soluble chromatin. Eur J Pharmacol. 2007 Dec 1;575(1-3):28-33. Epub 2007 Jul 31. [PubMed:17716648 ]
  2. Hollingshead LM, Faulds D: Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991 Oct;42(4):690-719. [PubMed:1723369 ]
  3. Bigioni M, Zunino F, Capranico G: Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Res. 1994 Jun 25;22(12):2274-81. [PubMed:8036155 ]
  4. Fukushima T, Ueda T, Uchida M, Nakamura T: Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol. 1993 Apr;57(2):121-30. [PubMed:8494991 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Willmore E, Errington F, Tilby MJ, Austin CA: Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem Pharmacol. 2002 May 15;63(10):1807-15. [PubMed:12034365 ]
  2. Zhou R, Wang Y, Gruber A, Larsson R, Castanos-Velez E, Liliemark E: Topoisomerase II-mediated alterations of K562 drug resistant sublines. Med Oncol. 1999 Sep;16(3):191-8. [PubMed:10523799 ]
  3. De Renzo A, Santoro LF, Notaro R, Pane F, Buonaiuto MR, Luciano L, Rotoli B: Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II. Am J Hematol. 1999 Apr;60(4):300-4. [PubMed:10203104 ]
  4. Gonzalez-Cid M, Fundia AF, Cuello MT, Larripa I: Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes. Toxicology. 2002 Feb 28;171(2-3):215-22. [PubMed:11836027 ]
  5. Bigioni M, Zunino F, Capranico G: Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Res. 1994 Jun 25;22(12):2274-81. [PubMed:8036155 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23